WASHINGTON and DALLAS, March 13, 2026 /PRNewswire/ -- The American College of Cardiology (ACC), the American Heart Association and nine other leading medical associations, today issued an updated ...

The recommendations focus on managing dyslipidemia, or abnormal blood lipid levels.

The ACC and AHA released updated guidelines for the management of dyslipidemia to reduce risk for atherosclerotic cardiovascular disease.

Inclisiran, an siRNA therapy, significantly reduces LDL-C by 28.5% in adolescents with heterozygous familial hypercholesterolemia (HeFH).

TORONTO, March 5, 2026 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and ...

Findings showed the trial met the primary endpoint, with enlicitide demonstrating a statistically significantly meaningful reduction in LDL-C compared with placebo. Topline data were announced from a ...

FDA expands Juxtapid approval for pediatric patients aged 2 years and older with homozygous familial hypercholesterolemia to ...

In patients with cardiovascular disease or who are at high risk for CVD, lerodalcibep significantly decreases LDL-C. Lerodalcibep significantly decreases low-density lipoprotein cholesterol (LDL-C) in ...

Compared with placebo, obicetrapib lowered LDL-C by 33% at day 84 (P .0001). Topline results were announced from a phase 3 trial evaluating obicetrapib, an investigational low dose cholesterol ester ...

In a traditional observational analysis, associations of LDL-C with incident chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and all-cause mortality were U-shaped or ...